NanoViricides targets broad-spectrum virus threats – ICYMI

Impact · against what's priced in

NanoViricides provides a significant value-inflection update by confirming the successful completion of Phase 1 trials with a clean safety profile and the transition to Phase 2 for Mpox. The filing for Rare Pediatric Disease Drug Designation further expands the potential commercial value and regulatory path for NV-387.

NNVC+0.70: No priced-in read yet
In context: The completion of Phase 1 with no adverse events and the progression to Phase 2 trials for Mpox in the DRC are material derisking milestones. Additionally, the RPDD filing for measles introduces potential regulatory advantages and exclusivity not previously captured.
Read from the article alone

NanoViricides targets broad-spectrum virus threats – ICYMI

biotech
NNVC
antiviral
clinical trials
fda
measles
mpox
nanomedicine
orphan drug
pharma
respiratory virus

NanoViricides targets broad-spectrum virus threats – ICYMI

What matters in this story

CSL strikes US$1.6 billion licensing deal for rare disease drug

NanoViricides targets broad-spectrum virus threats – ICYMI

What matters in this story

CSL strikes US$1.6 billion licensing deal for rare disease drug

How each ticker is affected

Track these names every morning.

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Iovance: Buy Now Before Many Growth Catalysts Kick In

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

NanoViricides targets broad-spectrum virus threats – ICYMI

What matters in this story

Next reads from the same story arc

CSL strikes US$1.6 billion licensing deal for rare disease drug

NanoViricides targets broad-spectrum virus threats – ICYMI

What matters in this story

Next reads from the same story arc

CSL strikes US$1.6 billion licensing deal for rare disease drug

How each ticker is affected

Track these names every morning.

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Iovance: Buy Now Before Many Growth Catalysts Kick In

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve